Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Nautilus Biotechnology Inc., 3 years.
Nautilus Biotechnology Inc.
Director
Roivant Sciences Ltd.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 24, 2024 | Roivant Sciences Ltd. | Grant or award | +1,146 | — | — |
| Apr 24, 2024 | Roivant Sciences Ltd. | Shares withheld for tax | −123 | $10.90 | $1,341 |
| Feb 12, 2024 | Zentalis Pharmaceuticals Inc. | Open-market sale | −2,573 | $11.44 | $29,435 |
| Feb 2, 2024 | Zentalis Pharmaceuticals Inc. | Open-market sale | −8,669 | $11.54 | $100,040 |
| Feb 1, 2024 | Zentalis Pharmaceuticals Inc. | Grant or award | +75,000 | — | — |
| Jan 19, 2024 | Roivant Sciences Ltd. | Grant or award | +1,207 | — | — |
| Oct 16, 2023 | Roivant Sciences Ltd. | Grant or award | +1,226 | — | — |
| Oct 4, 2023 | Zentalis Pharmaceuticals Inc. | Open-market sale | −4,594 | $19.43 | $89,261 |
| Oct 4, 2023 | Zentalis Pharmaceuticals Inc. | Open-market sale | −888 | $19.91 | $17,680 |
| Sep 12, 2023 | Roivant Sciences Ltd. | Grant or award | +17,825 | — | — |
| Jul 3, 2023 | Roivant Sciences Ltd. | Grant or award | +1,280 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.